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Abstract 
Background: Due to public stigma or self-stigma and shame, many adolescents with mental 
illness (MI) struggle with the decision whether to disclose their MI to others. Both disclosure 
and non-disclosure are associated with risks and benefits. Honest, Open, Proud (HOP) is a 
peer-led group program that supports participants with disclosure decisions in order to reduce 
stigma’s impact. Previously, HOP had only been evaluated among adults with MI. 
Methods: This two-arm pilot randomized controlled trial included 98 adolescents with MI. 
Participants were randomly assigned to HOP and treatment as usual (TAU) or to TAU alone. 
Outcomes were assessed pre (T0/baseline), post (T1/after the HOP program) and at 3-week 
follow-up (T2/six weeks after T0). Primary endpoints were stigma stress at T1 and quality of 
life at T2. Secondary outcomes included self-stigma, disclosure-related distress, 
empowerment, help-seeking intentions, recovery, and depressive symptoms. The trial is 
registered on ClinicalTrials (NCT02751229; http://www.clinicaltrials.gov). 
Results: Compared to TAU, adolescents in the HOP program showed significantly reduced 
stigma stress at T1 (d=0.92, p<.001) and increased quality of life at T2 (d=0.60, p=.004). In a 
longitudinal mediation model, the latter effect was fully mediated by stigma stress reduction 
at T1. HOP further showed significant positive effects on self-stigma, disclosure-related 
distress, secrecy, help-seeking intentions, attitudes to disclosure, recovery and depressive 
symptoms. Effects at T1 remained stable or improved further at follow-up. In a limited 
economic evaluation HOP was cost-efficient in relation to gains in quality of life.  
Conclusions: As HOP is a compact three-session program and showed positive effects on 
stigma and disclosure variables as well as on symptoms and quality of life, it could help to 
reduce stigma’s negative impact among adolescents with MI. 
Keywords: Randomized controlled trial; adolescents; mental illness; Honest, Open, Proud; 
Coming Out Proud; disclosure; secrecy  
Abbreviations: HOP - Honest, Open, Proud; MI - Mental illness  
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Introduction 
Adolescents with mental illness (MI) often experience stigma and discrimination which can 
have a severe impact on long-term clinical, social and vocational functioning (Kaushik, 
Kostaki, & Kyriakopoulos, 2016; Patel, Flisher, Hetrick, & McGorry, 2007). Unlike other 
stigmatized characteristics, MI is often invisible. Therefore many adolescents with MI 
struggle with the decision whether to disclose their condition to others. Disclosure may lead to 
labeling and discrimination, on the other hand it can offer opportunities for social support, 
facilitate help-seeking, increase authenticity and decrease the stress associated with secrecy 
(Pachankis, 2007). Given the consequences and irreversibility of disclosure, this can be a 
challenging decision and individuals may weigh the pros and cons differently. Honest, Open, 
Proud (HOP) is a peer-led group program that supports participants with MI in their 
disclosure decisions. HOP has so far only been evaluated in two RCTs among adults with MI 
(Corrigan et al., 2015; Rüsch, Abbruzzese et al., 2014), and both showed positive effects on 
stigma-related stress.  
The concept of stigma stress is based on stress-coping models of stigma (Lazarus & 
Folkman, 1984). It occurs when stigmatized individuals feel that stigma-related harm exceeds 
their coping resources (Rüsch et al., 2009). If, on the other hand, people feel confident to cope 
with stigma, their level of stigma stress will be low. As disclosure decisions as well as stigma 
itself can be stressful and HOP supports participants in these domains, stigma stress is a 
plausible proximal outcome of HOP as evidenced by the above-mentioned RCTs. Non-
interventional studies among adolescents and adults with MI showed consistent negative 
associations of stigma stress with quality of life and other aspects of well-being (Rüsch, 
Müller, Heekeren et al., 2014; Rüsch, Müller, Lay et al., 2014). We therefore expected that 
stigma stress reductions would lead to improved quality of life over time as a distal outcome. 
We conducted this pilot RCT to examine HOP’s efficacy to reduce the impact of 
mental illness stigma on adolescents with MI and investigated the economic impact of the 
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program in relation to mental health service use and quality of life outcomes. As two primary 
outcomes, compared to the control group we expected HOP to reduce short-term stigma stress 
after the 3-week program (T1); and to improve mid-term quality of life after the 3-week 
follow-up period (T2). As secondary outcomes, we expected improvements in other stigma- 
and disclosure-related and clinical outcomes after the intervention and at follow-up. 
 
Methods 
Trial design and participants 
In this two-arm 1:1-RCT, participants were randomly assigned to HOP, combined with 
treatment as usual (TAU), or to a control group that received only TAU. Participants were 
recruited from three Departments of Child and Adolescent Psychiatry (Ulm, Augsburg, 
Ravensburg-Weissenau) in southern Germany between May 2016 and February 2017. All 
departments had inpatient wards, day clinics and outpatient clinics. As the recruitment of 
participants from the three outpatient clinics was not sufficient, an independent child and 
adolescent psychiatry outpatient practice in Ulm was added as recruitment site. This practice 
treats adolescents comparable in illness severity and sociodemographic variables to other 
outpatient settings and mainly with attention deficit, conduct, anxiety or affective disorders. 
About one in four has a history of psychiatric inpatient treatment and access does not depend 
on the type of health insurance. 
Inclusion criteria for all participants were: at least one self-reported current axis-I or 
axis-II disorder according to ICD-10 (WHO, 2010) in response to a list of major diagnostic 
categories; age 13 to 18; ability to provide written informed consent; fluent German language 
skills; and at least a moderate level of self-reported disclosure-related distress (≥4 for ‘In 
general, how distressed or worried are you in terms of secrecy or disclosure of your mental 
illness to others?’, rated from 1/not at all to 7/very much). Exclusion criteria were intellectual 
disability; organic disorder; or diagnosis of only a substance- or alcohol-related disorder, 
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without non-substance related current psychiatric comorbidity, since disclosure of these 
disorders is not a topic specifically discussed in the HOP program. The trial was approved by 
the ethics committees of Ulm University and of the regional college of physicians. Parents or 
legal guardians as well as adolescents provided written informed consent after being fully 
informed about study procedures. Before including the first participants, the trial was 
registered on ClinicalTrials (NCT02751229; www.clinicaltrials.gov).  
 
Sample size 
Prior to this study, there were neither data on HOP’s efficacy among adolescents nor data on 
HOP in inpatient settings. Furthermore, the HOP version for adolescents differs from the 
program for adults that was evaluated in previous RCTs. Based on a power of 80% to detect 
an effect on at least one endpoint, alphas of 0.025, and two primary endpoints with an 
expected correlation of r=-0.3 (unpublished data), 100 participants were sufficient to detect 
medium effect sizes of d=0.5 on stigma stress, similar to effects on stigma stress in a previous 
adult HOP RCT (Rüsch, Abbruzzese et al., 2014), and d=0.4 on quality of life. 
 
Randomization 
After completing the baseline assessment (T0), participants were randomly assigned to the 
intervention (HOP+TAU) or the control group (TAU alone) by block randomization 
separately for each study center. Randomization lists and closed envelopes were generated by 
the Institute of Epidemiology and Medical Biometry, University of Ulm, Germany. Blinding 
of participants was not feasible, and research staff were not blinded as outcomes were 
assessed by self-report. To reduce the risk of contamination between trial arms, HOP 
participants were asked not to share HOP materials with control group participants.  
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HOP Intervention 
HOP’s goal is to support participants with the decision whether to disclose their MI in 
different settings. HOP was developed by Corrigan and colleagues based on a previous book 
(Corrigan & Lundin, 2001). It was previously known as ‘Coming Out Proud’ and is now 
called ‘Honest Open Proud’ (www.comingoutproudprogram.org). Originally it was developed 
for adults with MI. Sue McKenzie, Suzette Urbashich, WISE Wisconsin 
(https://wisewisconsin.org/), and Patrick W. Corrigan adapted HOP for adolescents with MI 
in the US. Following consultations with German peers and service users and based on the 
results of our focus group study among German adolescents with MI on disclosure (Mulfinger 
et al, submitted for publication), we translated and adapted the HOP adolescent version for the 
German context and added vignettes about disclosure and social media.  
As disclosure decisions depend on the setting and are very individual, HOP discusses 
levels of disclosure, settings of disclosure and how to choose persons to disclose to. It is not 
HOP’s aim to push participants towards disclosure, but to empower them to make their own 
decision. HOP is a peer-led group program that covers five themes; (i) Beliefs: Starting with 
stories of adolescents in the workbook, participants explore attitudes about having a MI and 
ways to challenge self-stigmatizing beliefs; (ii) Pros and Cons of Disclosure: Participants 
discuss short-term and long-term risks and benefits of (non-)disclosure in different settings, 
levels of disclosure and disclosure via social media; (iii) The right person: Participants learn 
how to find people that are good to disclose to and how to test them out before a potential 
disclosure, anticipating responses of others to one’s disclosure; (iv) Telling one’s story: After 
reading first-person accounts in the workbook, participants practice how to tell their story, if 
they decide to do so, and how to identify peers who could support them; and (v) the role of 
solidarity and peer support, a summary of lessons learnt during the program and next steps. 
Lessons are structured by vignettes, first-person accounts, worksheets, tables and role plays.  
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HOP was conducted in three two-hour sessions during a three-week period. In 
previous HOP RCTs among adults with MI, two peers with lived experience of MI facilitated 
the groups. Due to the adolescent participants and the predominantly inpatient setting in this 
study, groups were facilitated by a young adult peer with lived experience of MI and a young 
mental health professional. Before recruitment onset, peer and professional group facilitators 
attended a HOP training conducted by NR and NM. Prior to the RCT, all facilitators ran at 
least one HOP practice group. Manual fidelity in the practice groups was >80%.   
 
Fidelity 
In order to check manual fidelity, a checklist covering the HOP workbook content was 
adapted from a previously used HOP fidelity scale (Rüsch, Abbruzzese et al., 2014). One 
research assistant was present in every session and completed the fidelity checklist. Fidelity 
was high with 87-98% for lesson one, 86-97% for lesson two, and 79-85% for lesson three. 
Mean fidelity across sessions and sites was 89%. 
 
Measures 
Outcomes were measured at three timepoints: baseline (Pre/T0); immediately following the 
intervention, or three weeks after baseline for TAU-only participants (Post/T1); and 6 weeks 
after baseline (Follow-up/T2). We assessed two primary endpoints as defined a priori in the 
study protocol: Stigma stress reduction as proximal outcome at T1, and quality of life as distal 
outcome at T2. Stigma-stress was assessed by the 8-item Stigma Stress Scale (Rüsch et al., 
2009). Four items measured the primary appraisal of stigma as harmful (alphas in our study 
0.90/0.93/0.92 for T0/T1/T2) and four items the secondary appraisal of perceived resources to 
cope with stigma-related harm (alphas 0.70/0.77/0.89). All items were rated from 1 to 7, 
higher mean scores indicating more harm or more coping resources. A stigma stress score was 
computed by subtracting perceived resources from perceived harm, with higher difference 
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scores (range -6 to +6) indicating more stigma-stress. Health-related quality of life was 
measured with the KIDSCREEN-10 index (Ravens-Sieberer et al., 2010), with higher sum 
scores (range 10 to 50) indicating better quality of life (alphas 0.80/0.85/0.79).  
Secondary outcomes included empowerment as measured by the 9-item Self-Esteem 
and the 4-item Optimism subscales of the Empowerment Scale (Rogers, Chamberlin, Ellison, 
& Crean, 1997), with higher mean scores from 1 to 4 indicating stronger empowerment 
(alphas 0.91/0.93/0.91 and 0.56/0.73/0.77). Disclosure-related distress was examined by the 
above-mentioned screening item (Rüsch, Abbruzzese et al., 2014). Two items assessed 
attitudes towards disclosure in one’s personal or educational/professional environment, 
respectively (‘In general, how comfortable would you feel talking to a friend or family 
member [item 1; ‘... to a teacher or employer ...’ in item 2] about your mental health, for 
example, telling them you have a mental health diagnosis and how it affects you?’, from 1/not 
at all to 7/very much). Hopelessness was examined with the 4-item brief version of Beck’s 
Hopelessness Scale (Yip & Cheung, 2006), with higher sum scores from 4 to 24 equaling 
more hopelessness (alphas 0.85/0.81/0.78). Self-stigma was assessed by two measures. First, 
the 10-item Internalized Stigma of Mental Illness Inventory-Short Form (ISMI; Boyd, 
Otilingam, & Deforge, 2014) is a broad measure that includes experienced discrimination and 
social withdrawal, with higher mean scores between 1 and 4 indicating more self-stigma 
(alphas 0.80/0.76/0.80). Second, the 5-item self-concurrence/apply subscale of the Self-
Stigma of Mental Illness Scale-Short Form (SSMIS; Corrigan et al., 2012) assessed whether 
respondents applied negative stereotypes to themselves (alphas 0.70/0.75/0.81), higher sum 
scores from 5 to 45 equaling more self-stigma.  
Participants reported intentions to seek help for mental health problems from different 
sources in the General Help Seeking Questionnaire (Wilson, Deane, Ciarrochi, & Rickwood, 
2005), from 1/extremely unlikely to 7/extremely likely. Based on a factor analysis of help-
seeking intentions in an unrelated study (Waldmann et al., in preparation), we averaged 
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intentions to seek help from family/friends (items 1-4) and from professionals (items 5, 7, 10). 
Recovery was examined by the 4-item Self-Identified Stage of Recovery Scale (Andresen, 
Caputi, & Oades, 2010), higher sum scores from 4 to 24 indicating better recovery (alphas 
0.74/0.75/0.73). Secrecy and social withdrawal were assessed using Link’s Stigma Coping 
Orientation Scales (Link, Mirotznik, & Cullen, 1991), with higher mean scores from 1 to 6 
equaling more secrecy or withdrawal (alphas for 5 secrecy items 0.64/0.72/0.81; for 7 social 
withdrawal items 0.74/0.77/0.74). Depressive symptoms were assessed using the 15-item 
German version of the Center for Epidemiologic Studies-Depression Scale (Meyer & 
Hautzinger, 2001), with higher sum scores (range 0 to 45) indicating more depressive 
symptoms (alphas 0.83/0.83/0.83). At T1, HOP participants responded to an open-ended 
question what they liked or disliked about HOP and themes were summarized. 
 
Statistical analyses 
Baseline characteristics of dropouts (n=22) versus completers (n=76) after six weeks were 
compared using t-tests or chi-square tests. We analyzed intervention effects first by intention-
to-treat (ITT) analysis and a linear mixed model for repeated measures (MMRM; Ashbeck & 
Bell, 2016; Davis, 2014); and second by available case analysis using ANCOVAs. With two 
primary endpoints, we corrected the significance level for both to p<0.025. All other analyses 
were exploratory with p<0.05. 
Our MMRM analysis used a restricted maximum likelihood (REML)-based repeated-
measures approach. The analyses included the fixed, categorical effects of group, time point 
of measurement, and group-by-timepoint interaction as well as the fixed covariates of baseline 
score and center. An unstructured (co)variance structure shared across treatment groups was 
used to model the within-patient errors. The Kenward-Roger approximation was used to 
estimate denominator degrees of freedom and adjust standard errors. Analyses were 
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implemented with SAS PROC MIXED. Effect size d was calculated by dividing MMRM 
estimated group differences by the pooled standard deviation at baseline for each outcome. 
For ANCOVAs we used all available data which is more conservative than a per-
protocol analysis because participants who had been randomized to HOP but had not 
participated in all sessions were included (Figure 1). Intervention effects were tested using 
group as between- and time as within-subject factors; the baseline value of the respective 
outcome and center/site were used as covariates. Effect size estimates are provided as partial 
η², with η² of 0.10 or 0.25 indicating medium or large effect sizes (Vacha-Haase & 
Thompson, 2004). 
The hypothesized longitudinal mediation model of intervention effects on the two 
primary endpoints was tested using structural equation modeling within R version 3.3.3 
(lavaan library; Figure 2). Changes in stigma stress from Pre/T0 to Post/T1 (T0-T1, difference 
scores >0 indicating decreased stigma stress) as well as changes in quality of life from T0 to 
T2 (T2-T0, differences >0 indicating increased quality of life) were calculated. Missing data 
were accounted for by Full Information Maximum Likelihood estimation, and bootstrapping 
ensured robust standard errors (bootstrap replications=1000).  
To contextualize HOP outcomes in relation to program costs, we performed a limited 
threshold analysis, first to estimate the value of mental health service use which would need 
to be reduced for HOP to be economically efficient from a healthcare perspective and second 
to contextualize the quality of life outcomes. We estimated Quality Adjusted Life Years 
(QALYs) by mapping the KIDSCREEN-10 responses onto CHU9D utility scores using the 
algorithm recommended by Chen and colleagues (2014). 
 
Results 
Recruitment, assessment and baseline characteristics 
In total, we contacted 160 participants of whom 98 were included and randomized. With a 
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low refusal rate, adolescents were mainly excluded due to low disclosure-related distress or 
lack of parental consent (Figure 1). Recruitment ended when the approximate planned sample 
size was reached. There were no significant group differences between the HOP and control 
groups at baseline (Table 1; all p-values >.35). All participants completed questionnaires at 
baseline (T0), 84 (86 %) completed the post assessment (T1) and 76 participants (78 %) the 
follow-up assessment (T2). Baseline characteristics of the 22 participants lost to follow-up did 
not differ significantly from the 76 completers (Online Table 1). Recruitment from the 
outpatient practice proved more difficult than expected, as many potential outpatient 
participants did not report sufficient disclosure-related distress. Altogether, we included 85 
participants from inpatient settings (44 in the HOP, 41 in the control condition), 7 from 
hospital day-clinics, and 6 from the independent outpatient practice. No adverse events 
occurred among HOP or TAU participants.  
 
-- Insert Tables 1 and 2 and Figure 1 about here – 
 
Primary outcomes 
In the MMRM analysis, we found significant HOP effects with a large effect size on the 
proximal primary endpoint of stigma stress after 3 weeks/T1 (Table 2). Stigma stress 
continued to decrease among HOP participants at follow-up. With respect to our distal 
primary endpoint, we found a significant positive HOP effect on quality of life at follow-
up/T2 with a medium effect size. Results were very similar in the ANCOVAs (Online Table 
2).  
 
Secondary outcomes 
In terms of secondary outcomes (Table 2) we found significant and positive HOP effects on 
self-stigma both at T1 (at a trend-level for the ISMI scale) and at T2, with effect sizes 
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increasing from small to medium during follow-up. There were small, marginally significant 
short-term effects on empowerment in terms of self-esteem and optimism at T1 that lost 
significance at T2. Disclosure-related distress and secrecy were significantly reduced among 
HOP participants, with medium effect sizes at T1 and large effect sizes at T2. Social 
withdrawal decreased in the HOP group at T1. Intentions to seek help in one’s private 
environment or from healthcare professionals increased significantly in the HOP group at T1 
and remained significantly increased at T2 for professional help. HOP significantly reduced 
hopelessness at T2 in the available-case ANCOVA (Online Table 2) and at a trend level in 
MMRM (Table 2). Attitudes towards disclosure among family/friends and in school or 
employment settings improved significantly among HOP group participants at T1 and T2. 
There was a small-to-medium effect on recovery at T2 among HOP participants. Finally, HOP 
had a large effect on depressive symptoms at T2.  
 
-- Insert Figure 2 about here – 
 
Mediation analysis of intervention and both primary endpoints 
In the path model estimated by structural equation modeling, the positive association between 
the HOP program and increased quality of life at follow-up (T2) was fully mediated by 
decreased stigma stress after the intervention (T1; Figure 2). Due to estimating a saturated 
model (df=0), model fit could not be interpreted.  
 
Limited economic evaluation 
Costs for delivering HOP were estimated and included training peers and professionals, time 
for peers and professionals to deliver HOP, costs for printing training and HOP materials and 
venue hire. If we are very conservative and include the cost of training facilitators in addition 
to delivering HOP, program costs are estimated to be €154 per participant (€70 per participant 
 HOP for adolescents 13 
 
 
 
if excluding training and set up costs). Although representative data on costs of mental health 
service use for young people do not exist in Germany, we know from data in Britain that 
average annual costs associated with mental health service use for young people aged 5-15 are 
€1,697 when inflated to 2016 levels (Snell et al 2013). Given that health service utilization 
and spending tend to be higher in Germany compared to England 
(http://www.oecd.org/els/health-systems/health-data.htm), if one were aiming for neutrality in 
terms of treatment costs, HOP would be justified from the perspective of the health system if 
it were just to reduce a fraction of mental health service use. We could also contextualize the 
value of improved quality of life given that HOP also demonstrated an improvement in 
quality of life. Even if we were to include the costs of training HOP facilitators, relative to 
TAU, the utility gains of 0.044 points for those who received HOP vs TAU at T2 would 
translate to €20,533/QALY if the gains were only to last for 2 months and to €6,969/QALY if 
the gains were to last for 6 months - a reasonable investment given the standard National 
Institute for Clinical Excellence threshold value of £20,000-£30,000 (€25,552 - €38,828). 
 
Participants’ views 
Peer group facilitators were seen as inspiring role models. Participants liked to learn about 
other participants’ disclosure decisions and to hear their stories. They thought HOP improved 
their knowledge about disclosure and valued the clear structure of the workbook and its 
realistic scenarios. Participants liked the hands-on strategies how to talk about their MI and 
how to seek out persons to disclose to. Some felt relieved when talking about their MI in the 
safe group space. Participants highlighted the group interaction which was characterized by 
openness, trust and respect. Some felt the first module was too theoretical and demanding, 
others found it hard to concentrate or thought some material was too detailed.  
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Discussion 
Our findings support the feasibility, efficacy and cost-effectiveness of HOP for adolescents. 
While the rhythms of hospital wards offered a challenge, including the early discharge of 
some participants, dropout rates remained moderate. Our hypothesis that HOP would improve 
stigma stress, as a proximal outcome after the intervention, and that this would lead to 
improved quality of life at follow-up was supported. HOP also led to significant 
improvements across a broad range of outcomes, including self-stigma, disclosure variables, 
help-seeking intentions and depressive symptoms. We also observed weaker positive effects 
on recovery and empowerment. This is promising and suggests that HOP can improve clinical 
and social outcomes when added to standard care. The three-session HOP program could be a 
useful, cost-efficient and practical intervention as it is brief and can be delivered in a variety 
of settings. 
  This study has some implications for research and practice. Future studies should 
examine HOP’s feasibility and efficacy in different settings as well as HOP’s effect on actual 
disclosure decisions and the effects of these decisions on participants over time. As there are 
other interventions to reduce self-stigma, including narrative, psychoeducational and 
acceptance-based approaches (Tsang et al., 2016), future work should compare their efficacy 
among young people. Our findings suggest stronger HOP effects in this age group compared 
to previous RCTs among adults (Corrigan et al., 2015; Rüsch, Abbruzzese et al., 2014). 
Several explanations are possible and could be examined in future research: Young people 
may be more open to discuss and change their views on disclosure; they might be more 
optimistic to deal successfully with stigma; and they may have a larger social network than 
adults with a long history of MI and thus have better opportunities to test, practice and 
evaluate disclosure-related choices. Therefore interventions to reduce stigma’s impact may be 
particularly worthwhile in the early course of the illness (Gronholm et al., 2016). This is in 
line with a public health perspective that underlines the negative consequences of stigma for 
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adolescent mental health (Kaushik, Kostaki, & Kyriakopoulos, 2016) and the scarcity of 
appropriate interventions for this target group (Patel et al., 2007).  
 
Limitations 
Participants in our study were mainly recruited from inpatient settings and from only one 
independent outpatient practice which limits generalizability and conclusions about HOP in 
outpatient settings. Only a minority of approximately one in four outpatients appeared to be 
significantly distressed by disclosure decisions. Future HOP studies could examine its 
efficacy for that group and might consider a lower disclosure distress threshold. The three-
week follow-up period was brief and long-term effects remain unclear. Likewise the efficacy 
of a booster session to maintain short- and mid-term effects should be examined in future 
studies. We cannot rule out contamination between trial arms. Research staff were not blinded 
to group allocation. Although we collected data on intervention costs, the economic analysis 
is limited as we did not have cost data beyond intervention delivery. Future research should 
measure the impact of HOP on health service use, as reduced symptoms could lead to reduced 
service use while increased help-seeking intentions could lead to increased service use. 
Reduced stigma stress and increased help-seeking from friends/peers and family may also 
impact social relationships and educational performance; costs associated with these 
outcomes could also be considered in future studies in addition to the potential for HOP to 
increase participants’ confidence in seeking future employment or other opportunities 
associated with potential economic impact. 
 
Conclusions 
If our findings are corroborated by future research, HOP can support adolescents with MI in 
their disclosure decisions and help them cope with stigma and discrimination. HOP has the 
potential to improve clinical outcomes as well as the recovery and well-being of adolescents.  
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Key points 
• Adolescents with mental illness (MI) may decide to conceal their condition in order to 
avoid stigma and discrimination.  
• Honest, Open, Proud (HOP) is a manualized peer-led group program that supports 
participants with MI with disclosure decisions in order to reduce stigma’s impact.  
• HOP for adolescents appears to be a safe, feasible and cost-efficient intervention for 
adolescents with MI that has significant positive effects on stigma-related stress, quality 
of life, self-stigma, disclosure-related distress, secrecy, help-seeking intentions, attitudes 
to disclosure, recovery and depressive symptoms.  
 
Acknowledgement and Funding 
This study was supported by the Nachwuchsakademie Versorgungsforschung Baden-
Württemberg and the Kässbohrer Foundation. We are grateful to participants and group 
facilitators and for feedback on the economic analysis by Professor Martin Knapp. We thank 
our WISE colleagues Sue McKenzie and Suzette Urbashich for letting us adapt their HOP 
version. 
 
Correspondence 
Address correspondence to Nicolas Rüsch, Section of Public Mental Health, Department of 
Psychiatry II, Ulm University and BKH Günzburg, Parkstr. 11, D-89073 Ulm, Germany. 
Phone: +4973150062301, Fax +4973150062302, Email: nicolas.ruesch@uni-ulm.de 
 
  
 HOP for adolescents 17 
 
 
 
References 
Andresen, R., Caputi, P., & Oades, L.G. (2010). Do clinical outcome measures assess consumer-defined 
recovery? Psychiatry Research, 177(3), 309–317. 
Ashbeck, E.L., & Bell, M.L. (2016). Single time point comparisons in longitudinal randomized trials: 
Power and bias in the presence of missing data. BMC Medical Research Methodology, 16, 43. 
Boyd, J.E., Otilingam, P.G., & Deforge, B.R. (2014). Brief version of the Internalized Stigma of Mental 
Illness (ISMI) scale: psychometric properties and relationship to depression, self esteem, recovery 
orientation, empowerment, and perceived devaluation and discrimination. Psychiatric Rehabilitation 
Journal, 37(1), 17–23. 
Chen G, Stevens K, Rowen D, Ratcliffe J (2014). From KIDSCREEN-10 to CHU9D: creating a unique 
mapping algorithm for application in economic evaluation. Health and Quality of Life Outcomes, 12, 
134. 
Corrigan, P.W., Larson, J.E., Michaels, P.J., Buchholz, B.A., Rossi, R.D., Fontecchio, M.J., Castro, D., 
Gause, M., Krzyżanowski, R., & Rüsch, N. (2015). Diminishing the self-stigma of mental illness by 
coming out proud. Psychiatry Research, 229(1-2), 148–154. 
Corrigan, P.W., & Lundin, R. (2001). Don't Call Me Nuts: Coping with the Stigma of Mental Illness: 
Recovery Press. 
Corrigan, P.W., Michaels, P.J., Vega, E., Gause, M., Watson, A.C., & Rüsch, N. (2012). Self-stigma of 
mental illness scale--short form: reliability and validity. Psychiatry Research, 199(1), 65–69. 
Davis, S. (2014). Mixed models for repeated measures using categorical time effects (MMRM). In: 
Clinical Trials with Missing Data, Eds. O'Kelly M., Ratitch, B., Wiley, Chichester, pp. 130-184. 
Gronholm, P., Thornicroft, G., Laurens, K., Evans-Lacko, S. (2017). Conditional disclosure on 
pathways to care: Coping preferences of young people at risk of psychosis. Qualitative Health 
Research 27(12):1842-1855. 
Kaushik, A., Kostaki, E., & Kyriakopoulos, M. (2016). The stigma of mental illness in children and 
adolescents: A systematic review. Psychiatry Research, 243, 469–494. 
 HOP for adolescents 18 
 
 
 
Lazarus, R.S., & Folkman, S. (1984). Stress, Appraisal, and Coping. New York: Springer. 
Link, B.G., Mirotznik, J., & Cullen, F.T. (1991). The effectiveness of stigma coping orientations: can 
negative consequences of mental illness labeling be avoided? Journal of Health and Social Behavior, 
32(3), 302–320. 
Meyer, T. D., & Hautzinger, M. (2001). Allgemeine Depressions-Skala. Diagnostica, 47(4), 208–215. 
Pachankis, J.E. (2007). The psychological implications of concealing a stigma: a cognitive-affective-
behavioral model. Psychological Bulletin, 133(2), 328–345. 
Patel, V., Flisher, A.J., Hetrick, S., & McGorry, P. (2007). Mental health of young people: a global 
public-health challenge. Lancet, 369(9569), 1302–1313. 
Ravens-Sieberer, U., Erhart, M., Rajmil, L., Herdman, M., Auquier, P., Bruil, J., Power, M., Duer, W., 
Abel, T., Czemy, L., Mazur, J., Czimbalmos, A., Tountas, Y., Hagquist, C., & Kilroe, J. (2010). 
Reliability, construct and criterion validity of the KIDSCREEN-10 score: a short measure for 
children and adolescents' well-being and health-related quality of life. Quality of Life Research, 
19(10), 1487–1500. 
Rogers, E.S., Chamberlin, J., Ellison, M.L., & Crean, T. (1997). A consumer-constructed scale to 
measure empowerment among users of mental health services. Psychiatric Services, 48(8), 1042–
1047. 
Rüsch, N., Abbruzzese, E., Hagedorn, E., Hartenhauer, D., Kaufmann, I., Curschellas, J., Ventling, S., 
Zuaboni, G., Bridler, R., Olschewski, M., Kawohl, W., Rössler, W., Kleim, B., & Corrigan, P.W. 
(2014). Efficacy of Coming Out Proud to reduce stigma's impact among people with mental illness: 
pilot randomised controlled trial. British Journal of Psychiatry, 204, 391–397. 
Rüsch, N., Corrigan, P.W., Heekeren, K., Theodoridou, A., Dvorsky, D., Metzler, S., Müller, M., 
Walitza, S., & Rössler, W. (2014). Well-being among persons at risk of psychosis: the role of self-
labeling, shame, and stigma stress. Psychiatric Services, 65(4), 483–489. 
Rüsch, N., Corrigan, P.W., Wassel, A., Michaels, P., Olschewski, M., Wilkniss, S., & Batia, K. (2009). 
A stress-coping model of mental illness stigma: I. Predictors of cognitive stress appraisal. 
 HOP for adolescents 19 
 
 
 
Schizophrenia Research, 110(1-3), 59–64. 
Rüsch, N., Müller, M., Heekeren, K., Theodoridou, A., Metzler, S., Dvorsky, D., Corrigan, P.W., 
Walitza, S., & Rössler, W. (2014). Longitudinal course of self-labeling, stigma stress and well-being 
among young people at risk of psychosis. Schizophrenia Research, 158(1-3), 82–84. 
Rüsch, N., Müller, M., Lay, B., Corrigan, P.W., Zahn, R., Schönenberger, T., Bleiker, M., Lengler, S., 
Blank, C., & Rössler, W. (2014). Emotional reactions to involuntary psychiatric hospitalization and 
stigma-related stress among people with mental illness. European Archives of Psychiatry and 
Clinical Neuroscience, 264(1), 35–43. 
Snell, T., Knapp, M., Healey, A., Guglani, S., Evans-Lacko, S., Meltzer, H., & Ford, T. (2013). The 
economic impact of childhood psychiatric disorder on public sector services in Britain: estimates 
based on national survey data. Journal of Child Psychology and Psychiatry, 54, 977-985. 
Tsang, H.W.H., Ching, S.C., Tang, K.H., Lam, H.T., Law, P.Y.Y., & Wan, C.N. (2016). Therapeutic 
intervention for internalized stigma of severe mental illness: A systematic review and meta-analysis. 
Schizophrenia Research, 173(1-2), 45–53. 
Vacha-Haase, T., & Thompson, B. (2004). How to estimate and interpret various effect sizes. Journal of 
Counseling Psychology, 51, 473–481. 
Wilson, C.J., Deane, F.P., Ciarrochi, J.V., & Rickwood, D. (2005). Measuring help-seeking intentions: 
Properties of the General Help-Seeking Questionnaire. Canadian Journal of Counselling, 39(1), 15–
28. 
WHO (2010). International Statistical Classification of Diseases and Related Health Problems (10th 
revision). Geneva: WHO. 
Yip, P.S.F., & Cheung, Y.B. (2006). Quick assessment of hopelessness: a cross-sectional study. Health 
and Quality of Life Outcomes, 4, 13. 
 
 
  
 HOP for adolescents 20 
 
 
 
Figure 1. Flowchart of participants 
 
  
Excluded (n=62) 
35 did not meet inclusion criteria (34 low 
level of disclosure-related distress; 1 
intellectual disability) 
20 no written informed consent from 
parents 
7 declined to participate 
 
Analysed (n=49) 
n=10 lost 
Discontinued intervention (5 refused, 5 could 
not be contacted) 
Allocated to HOP intervention (n=49) 
49 received allocated intervention (33 three 
sessions; 7 two sessions; 9 one session) 
n=4 lost 
Discontinued (4 could not be contacted) 
 
Analysed (n=49) 
 
Analysis 
Post (T1) 
n=11 lost 
Discontinued (5 refused, 6 could not be 
contacted) 
n=11 lost 
Discontinued (11 could not be contacted) 
 
Follow-Up (T2) 
Allocated to control (n=49) 
 
 
Assessed for eligibility (n=160) 
Randomized (n=98) 
Allocation 
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Figure 2.  Longitudinal path model of intervention effect on quality of life at follow-up/T2, 
mediated by stigma stress reduction after the intervention/T1. Structural equation modeling 
with standardized coefficients, N=98, indirect (mediated) effect 0.17, p=.03; total effect 0.30, 
p=.01;  * p<0.05, ***p<0.001 
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Table 1. Baseline characteristics of participants (HOP, n=49, versus Control group, n=49) 
 
 HOP 
M (SD)  
or n (%) 
Control 
M (SD)  
or n (%) 
Sociodemographic variables   
Age, years 15.8 (1.2) 15.7 (1.1) 
Female 33 (67 %) 35 (71 %) 
Born in Germany 47 (96 %) 46 (94 %) 
Clinical and diagnostic variables   
Number of psychiatric inpatient treatments  
(incl. current for inpatient participants) 
1.5 (1.2), 
Median 1, 
range 0 - 5 
1.7 (1.6) 
Median 1,  
range 0 – 10 
Months since first diagnosis 
21.5 (32.4) 
Median 9, 
range 0.5 - 144 
23.5 (32.3) 
Median 12,  
range 1 - 132 
Depressive Disorder 30 (64 %) 28 (58 %) 
Anxiety Disorder 9 (19 %) 8 (17 %) 
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Table 2. Mixed model for repeated measures (MMRM, bold for primary endpoints). Positive group differences indicate an increase of the respective 
outcome in the HOP group as compared to the control condition, and vice versa for negative estimates. For means and SD of available 
cases at T0, T1 and T2 see Online Table 2. 
 Estimated group differences: M (95%-CI) T1 (post) T2 (follow-up) 
 Post (T1) Follow-up (T2) T d p T d p 
Stigma Stress a -2.06  (-2.70  –  -1.42) -2.16  (-2.89  –  -1.43) -6.41 0.92 <.001 -5.89 0.96 <.001 
Quality of Life b 0.82  (-1.34  –  2.98) 3.54  (1.14  –  5.93) 0.75 0.14 0.45 2.94 0.60 0.004 
Self-Stigma (ISMI) c  -0.16  (-0.33  –  0.01) -0.35  (-0.54  –  -0.16) -1.92 0.28 0.058 -3.61 0.61 <.001 
Self-Stigma (SSMIS) d -2.93  (-5.35  –  -0.52) -5.14  (-8.22  –  -2.05) -2.42 0.36 0.018 -3.32 0.63 0.001 
Empowerment/Self-esteem e 0.21  (0.04  –  0.39)  0.19  (-0.03  –  0.41) 2.43 0.29 0.017 1.71 0.26 0.09 
Empowerment/Optimism e 0.20  (0  –  0.40) 0.21  (-0.03  –  0.46) 1.95 0.33 0.055 1.71 0.35 0.09 
Disclosure-related distress  -0.87  (-1.37  –  -0.37) -1.18  (-1.85  –  -0.51) -3.45 0.53 <.001 -3.51 0.71 <.001 
Secrecy f  -0.44  (-0.79  –  -0.08) -0.78  (-1.16  –  -0.40) -2.44 0.46 0.016 -4.07 0.81 <.001 
Social withdrawal f -0.34  (-0.63  –  -0.05) -0.29  (-0.66  –  0.08) -2.31 0.34 0.023 -1.55 0.29 0.12 
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Help-seeking 
(family/friends) g  
0.77  (0.36  –  1.17) 0.48  (-0.02  –  0.98) 3.79 0.55 <.001 1.93 0.34 0.057 
Help-seeking (professional) g 0.60  (0.15  –  1.05) 0.82  (0.32  –  1.32) 2.64 0.47 0.010 3.26 0.64 0.002 
Hopelessness h -0.51  (-1.88  –  0.85) -1.22  (-2.68  –  0.24) -0.75 0.10 0.46 -1.66 0.23 0.10 
Attitudes to disclosure  
(to family/friends)  
1.00  (0.43  –  1.57) 1.02  (0.43  –  1.61) 3.52 0.62 <.001 3.43 0.64 0.001 
Attitudes to disclosure  
(to teacher/employer)  
0.66  (0.15  –  1.16) 0.91  (0.28  –  1.53) 2.59 0.46 0.011 2.88 0.64 0.005 
Stage of recovery i 0.15  (-1.34  –  1.64) 1.59  (0.10  –  3.07) 0.20 0.03 0.85 2.13 0.35 0.037 
Depressive symptoms j -1.25  (-4.87  –  2.38) -7.25  (-10.85  –  -3.65) -0.68 0.12 0.50 -4.00 0.72 <0.001 
 
 
a Stigma Stress Scale (Rüsch et al., 2009);  b KIDSCREEN-10 Index (Ravens-Sieberer et al., 2010);  c Internalized Stigma of Mental Illness Inventory, Short Form 
(Boyd et al., 2014);  d Self-Stigma of Mental Illness Scale-Short Form, subscale apply/self-concurrence (Corrigan et al., 2012);  e Empowerment Scale (Rogers et 
al., 1997);  f Stigma Coping Orientation Scales (Link et al., 1991);  g General Help Seeking Questionnaire (Wilson et al., 2005);  h Beck Hopelessness Scale, Short 
Version (Yip & Cheung, 2006);  i Self-Identified Stage of Recovery Scale (Andresen et al., 2010);  j Center for Epidemiologic Studies Depression Scale (Meyer 
& Hautzinger, 2001) 
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Online Table 1. Baseline/T0 characteristics of completers vs. dropouts 
   
 Completers 
(at T2, n=76) 
M (SD)  
or n (%) 
Dropouts 
(at T2, n=22) 
M (SD)  
or n (%) T χ2 p 
Sociodemographic 
variables 
     
Age, years 15.7 (1.1) 15.8 (1.4) 0.33  0.74 
Female 54 (71 %) 14 (64 %)  0.44 0.51 
Born in Germany 73 (96 %) 20 (91 %)  0.93 0.33 
Clinical variables      
Depressive symptoms a 26.1 (9.9) 23.9 (10.6) -0.90  0.37 
Number of psychiatric 
inpatient treatments (incl. 
current) 
1.6 (1.5) 1.6 (1.2) 0.08  0.94 
Months since first diagnosis 22.6 (32.3) 22.2 (32.5) -0.05  0.96 
Depressive Disorder 49 (65 %) 9 (41 %)  1.87 0.17 
Anxiety Disorder 15 (20 %) 2 (11 %)  0.88 0.35 
Disclosure variables      
Attitudes to disclosure 
(teacher/employer) 
2.1 (1.4) 2.3 (1.6) 0.52  0.61 
Attitudes to disclosure 
(family/friends) 
2.9 (1.6) 3.1 (1.8) 0.49  0.62 
Disclosure-related distress b 4.8 (1.6) 4.1 (1.8) -1.70  0.09 
 
a Center for Epidemiologic Studies-Depression Scale (Meyer & Hautzinger, 2001) 
b ‘In general, how distressed or worried are you with respect to secrecy or disclosure of your 
mental illness to others?’, rated from 1/not at all to 7/very much 
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Online Table 2. ANCOVAs for HOP and control groups (baseline score of each outcome and center as covariates; primary endpoints in bold print) 
   T1 T2 
  
Baseline/T0 
M (SD) 
Post/T1 
M (SD) 
Group dif-
erence T1 
M (95%-CI) 
Follow-
up/T2 
M (SD) 
Group dif- 
ference T2 
M (95%-CI) F 
par-
tial η2 p F 
par-
tial η2 p 
Stigma Stress a 
HOP 
Control 
-0.07 (2.37) 
-0.35 (2.13) 
-2.33 (1.91) 
-0.29 (2.01) 
-2.04  
(-2.89  –  -1.18) 
-2.56 (1.95) 
-0.28 (2.09) 
-2.28  
(-3.20  –  -1.35) 
41.7 0.34 <.001 33.9 0.32 <.001 
Quality of Life b 
HOP 
Control 
28.97 (5.95) 
28.92 (5.83) 
30.32 (7.37) 
28.97 (6.92) 
1.36  
(-1.75  –  4.46) 
32.97 (5.92) 
28.80 (6.34) 
4.17  
(1.33  –  7.01) 
0.7 0.01 0.40 9.7 0.12 0.003 
Self-Stigma  
(ISMI) c  
HOP 
Control 
2.38 (0.62) 
2.30 (0.54) 
2.18 (0.56) 
2.32 (0.48) 
-0.14  
(-0.37  –  0.08) 
2.04 (0.48) 
2.33 (0.57) 
-0.29  
(-0.53  –  -0.05) 
4.3 0.05 0.040 10.9 0.13 0.001 
Self-Stigma  
(SSMIS) d 
HOP 
Control 
21.57 (8.58) 
20.63 (7.64) 
17.09 (7.43) 
20.11 (8.75) 
-3.02  
(-6.58  –  0.53) 
15.16 (7.37) 
20.21 (10.23) 
-5.05  
(-9.14  –  -0.97)  
6.6 0.08 0.012 11.1 0.13 0.001 
Empowerment/ 
Self-esteem e 
HOP 
Control 
2.33 (0.78) 
2.31 (0.66) 
2.61 (0.76) 
2.33 (0.70) 
0.28 
(-0.04   –  0.60) 
2.69 (0.61) 
2.43 (0.70) 
0.27 
(-0.03  –  0.57) 
6.6 0.08 0.012 2.6 0.03 0.11 
Empowerment/ 
Optimism e 
HOP 
Control 
2.43 (0.60) 
2.49 (0.60) 
2.65 (0.62) 
2.46 (0.69) 
0.19  
(-0.10  –  0.47) 
2.70 (0.62) 
2.51 (0.77) 
0.19 
(-0.13 –  0.51) 
4.6 0.05 0.036 2.1 0.03 0.16 
Disclosure-related 
distress  
HOP 
Control 
4.70 (1.65) 
4.61 (1.68) 
3.92 (1.20) 
4.78 (1.44) 
-0.86  
(-1.44  –  -0.27) 
3.43 (1.53) 
4.74 (1.41) 
-1.30 
(-1.97  –  -0.63) 
11.8 0.13 0.001 14.4 0.17 <.001 
Secrecy f  
HOP 
Control 
3.74 (0.83) 
3.78 (1.09) 
3.31 (0.85) 
3.86 (1.12) 
-0.54  
(-0.98  –  -0.11) 
3.15 (0.96) 
4.01 (1.02) 
-0.86 
(-1.32  –  -0.41) 
6.3 0.07 0.014 16.0 0.18 <.001 
Social withdrawal f 
HOP 
Control 
4.04 (0.91) 
4.04 (1.09) 
3.71 (0.98) 
4.14 (1.03) 
-0.44  
(-0.88  –  0.00) 
3.70 (0.94) 
4.17 (1.05) 
-0.48 
(-0.93  –  -0.02) 
5.9 0.07 0.017 3.1 0.04 0.09 
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Help-seeking 
(family/friends) g  
HOP 
Control 
3.44 (1.36) 
3.30 (1.45) 
4.28 (1.32) 
3.31 (1.39) 
0.97 
(0.37  –  1.56) 
4.17 (1.32) 
3.35 (1.40) 
0.82 
(0.20  –  1.45) 
14.5 0.15 <.001 5.5 0.07 0.022 
Help-seeking 
(professional) g 
HOP 
Control 
3.59 (1.31) 
3.63 (1.28) 
4.37 (1.15) 
3.65 (1.40) 
0.72 
(0.16  –  1.28) 
4.61 (1.12) 
3.63 (1.41) 
0.97 
(0.39  –  1.55) 
8.6 0.10 0.004 11.7 0.14 0.001 
Hopelessness h 
HOP 
Control 
14.42 (5.32) 
14.82 (5.11) 
13.18 (4.51) 
14.39 (4.81) 
-1.21 
(-3.24  –  0.82) 
11.74 (3.83) 
13.95 (4.78) 
-2.21 
(-4.19  –  -0.23) 
0.5 0.01 0.48 4.2 0.06 0.043 
Attitudes to 
disclosure (to 
family/friends)  
HOP 
Control 
3.10 (1.62) 
2.83 (1.59) 
4.21 (1.40) 
3.00 (1.61) 
1.21 
(0.55  –  1.87) 
4.13 (1.44) 
2.82 (1.56) 
1.32 
(0.63  –  2.00) 
12.3 0.13 0.001 10.8 0.13 0.002 
Attitudes to 
disclosure (to 
teacher/employer)  
HOP 
Control 
2.00 (1.24) 
2.27 (1.58) 
2.60 (1.33) 
2.00 (1.13) 
0.60 
(0.06  –  1.14) 
2.86 (1.52) 
1.95 (1.25) 
0.91 
(0.27  –  1.54) 
7.0 0.08 0.010 9.6 0.12 0.003 
Stage of recovery i 
HOP 
Control 
14.64 (4.80) 
14.92 (4.35) 
15.48 (4.20) 
15.02 (4.70) 
0.46 
(-1.49  –  2.40) 
16.67 (4.13) 
14.73 (4.29) 
1.94 
(0.00  –  3.88) 
0.1 0.002 0.72 3.6 0.05 0.06 
Depressive 
symptoms j 
HOP 
Control 
26.22 (10.05) 
24.92 (10.16) 
22.28 (11.34) 
23.58 (10.94) 
-1.30 
(-6.14  –  3.55) 
18.16 (10.27) 
24.71 (11.24) 
-6.55 
(-11.47 –  -1.63) 
0.6 0.01 0.43 14.0 0.16 <.001 
 
 
a Stigma Stress Scale (Rüsch et al., 2009);  b KIDSCREEN-10 Index (Ravens-Sieberer et al., 2010);  c Internalized Stigma of Mental Illness Inventory, Short Form 
(Boyd et al., 2014);  d Self-Stigma of Mental Illness Scale-Short Form, subscale apply/self-concurrence (Corrigan et al., 2012);  e Empowerment Scale (Rogers et 
al., 1997);  f Stigma Coping Orientation Scales (Link et al., 1991);  g General Help Seeking Questionnaire (Wilson et al., 2005);  h Beck Hopelessness Scale, Short 
Version (Yip & Cheung, 2006);  i Self-Identified Stage of Recovery Scale (Andresen et al., 2010);  j Center for Epidemiologic Studies-Depression Scale (Meyer 
& Hautzinger, 2001)  
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Online Table 3. CONSORT checklist 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page 
No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and 
conclusions  
 
2 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 3-4 
2b Specific objectives or hypotheses 4 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including 
allocation ratio 
 
4 
3b Important changes to methods after trial commencement (such 
as eligibility criteria), with reasons 
 
- 
Participants 4a Eligibility criteria for participants 4-5 
4b Settings and locations where the data were collected 4 
Interventions 5 The interventions for each group with sufficient details to allow 
replication, including how and when they were actually 
administered 
 
 
6-7 
Outcomes 6a Completely defined pre-specified primary and secondary 
outcome measures, including how and when they were assessed 
 
7-9 
6b Any changes to trial outcomes after the trial commenced, with 
reasons 
 
- 
Sample size 7a How sample size was determined 5 
7b When applicable, explanation of any interim analyses and 
stopping guidelines 
 
- 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 5 
8b Type of randomisation; details of any restriction (such as 
blocking and block size) 
 
5 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence 
(such as sequentially numbered containers), describing any steps 
taken to conceal the sequence until interventions were assigned 
 
5 
 Implementation 10 Who generated the random allocation sequence, who enrolled 
participants, and who assigned participants to interventions 
 
5 
Blinding 11a If done, who was blinded after assignment to interventions (for 
example, participants, care providers, those assessing outcomes) 
and how 
 
 
5 
11b If relevant, description of the similarity of interventions - 
Statistical methods 12a Statistical methods used to compare groups for primary and 
secondary outcomes 
 
9-10 
12b Methods for additional analyses, such as subgroup analyses and  
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adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly 
assigned, received intended treatment, and were analysed for the 
primary outcome 
 
10-11 and 
Figure 1 
13b For each group, losses and exclusions after randomisation, 
together with reasons 
 
Figure 1 
Recruitment 14a Dates defining the periods of recruitment and follow-up 4 
14b Why the trial ended or was stopped 11 
Baseline data 15 A table showing baseline demographic and clinical 
characteristics for each group 
 
Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included 
in each analysis and whether the analysis was by original 
assigned groups 
 
 
Figure 1 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, 
and the estimated effect size and its precision (such as 95% 
confidence interval) 
 
 
Table 2 
17b For binary outcomes, presentation of both absolute and relative 
effect sizes is recommended 
 
- 
Ancillary analyses 18 Results of any other analyses performed, including subgroup 
analyses and adjusted analyses, distinguishing pre-specified 
from exploratory 
13 f., 
Figure 2, 
Online 
Tables 1 
and 2 
Harms 19 All important harms or unintended effects in each group  11 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, 
imprecision, and, if relevant, multiplicity of analyses 
 
15 
Generalisability 21 Generalisability (external validity, applicability) of the trial 
findings 
 
15 
Interpretation 22 Interpretation consistent with results, balancing benefits and 
harms, and considering other relevant evidence 
 
14 
Other information  
Registration 23 Registration number and name of trial registry 2; 5 
Protocol 24 Where the full trial protocol can be accessed, if available 2; 5 
Funding 25 Sources of funding and other support (such as supply of drugs), 
role of funders 
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